StockNews.AI
OMDA
StockNews.AI
21 days

New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation, Challenging Industry Assumptions

1. 63% of Omada members maintained weight after stopping GLP-1s, refuting typical weight regain. 2. Average weight change was just 0.8% after one year off GLP-1s. 3. Omada supported over 100,000 members on GLP-1 medications. 4. Employers can save on healthcare costs due to effective weight maintenance support. 5. Omada emphasizes ongoing lifestyle support in weight health management.

8m saved
Insight
Article

FAQ

Why Bullish?

The encouraging results on weight maintenance exemplify Omada's effective health management, which could attract more corporate clients seeking to reduce healthcare costs. Historical data, such as the rise in user adoption of Omada's programs after previous positive analyses, supports this outlook.

How important is it?

The findings are significant in the context of Omada's market, potentially driving more users and customers due to financial and health considerations demonstrated through their research.

Why Long Term?

The results highlighted in Omada's research lay a foundation for sustained engagement and long-term adoption of their health services, which typically contributes to steadily increasing revenue streams and market position.

Related Companies

AMGNNVCRCVACPFEINTU
Analysis shows Omada members maintained weight, with minimal (0.8%) average weight change, one year after discontinuing GLP-1s for weight loss,1 suggesting the impact of continued lifestyle support from Omada September 08, 2025 09:00 ET  | Source: Omada Health, Inc. SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months after discontinuing GLP-1s,1 challenging widespread assumptions of inevitable post-medication weight regain. Since the GLP-1 Care Track launched, Omada has supported more than 100,000 members taking GLP-1 medications. The retrospective analysis included 816 members in Omada’s GLP-1 Care Track and examined GLP-1 discontinuation and subsequent weight change at 6, 9, and 12 months.1 At one year post-discontinuation members showed just 0.8% average weight change,1 compared to 11-12% weight gain typically seen in clinical trials2-3 where participants do not always have access to wraparound lifestyle support after they stop the medication.3 Omada’s analysis demonstrated participants largely experienced weight maintenance consistently throughout the year, with 0.03% average weight change at 6 months and 0.6% average weight change at 9 months,1 suggesting the sustained impact of lifestyle support at this critical moment in their GLP-1 journey. "As employers face mounting pressure to manage the rising costs of GLP-1s,4 these findings demonstrate how Omada’s program can help prevent wasted healthcare dollars and protect the investment in these expensive medications," said Wei-Li Shao, President, Omada Health. "We believe that GLP-1 success includes both weight loss and weight maintenance. These findings show that proper support can help members maintain weight loss long after they decide along with their provider to discontinue GLP-1s,1 delivering lasting value to members and customers." The analysis used claims-based methodology to track outcomes of members without diabetes enrolled in Omada’s GLP-1 Care Track at 6, 9, and 12 months post-discontinuation.1 Omada offers behavioral support through dedicated care teams alongside connected devices and an AI-enhanced digital experience. Omada's program emphasizes the importance of maintaining muscle mass in members’ GLP-1 journeys, through activity and movement guidance for a holistic approach to weight health. "While our previous research showed promising short-term results after GLP-1 discontinuation,5 this analysis strengthens those findings by using objective pharmacy claims data and demonstrating that success can be sustained in the long-term,1" said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research at Omada Health. "As we see an increase in GLP-1 use,6 it's crucial that we understand how to support members at all phases of their weight health journey, including helping members maintain weight after discontinuing GLP-1s." This study was completed as part of the Omada Insights Lab ANSWERS (Analyzing Success of Weight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada’s behavior change weight health programs. Learn more about Omada Health’s approach to GLP-1 medications and coverage here. Omada HealthOmada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 30 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada’s scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s. The foundation of Omada’s success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently. Great Place to Work® is the registered trademark of the Great Place to Work Institute and is used under license. ContactsRose Ramsethpress@omadahealth.com Citations Chang H, Devaraj SM, Naqvi JB, Napoleone J, Linke S. Weight maintenance is possible after GLP-1s—with the right support. Omada Health. Published September 8, 2025. Accessed September 8, 2025. https://resourcecenter.omadahealth.com/white-papers/weight-maintenance-is-possible-after-glp-1s-with-the-right-support.Aronne, L.J., Sattar, N., Horn, D.B., et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725Mercer. Survey on health & benefit strategies for 2026 [PDF]. Mercer. Published July 2025. Accessed August 14, 2025. https://www.mercer.com/assets/us/en_us/shared-assets/local/attachments/pdf-2025-us-survey-on-health-and-benefit-strategies-for-2026.pdf.Naqvi JB, Chang H, Berthoumieux A, Linke S, Napoleone J. Maintaining weight loss after GLP-1s: outcomes of a 16-week analysis. Omada Health. Published January 2025. Accessed August 11, 2025. https://resourcecenter.omadahealth.com/latest-content/omada-health-maintaining-weight-loss-after-glp-1s.Mahase E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ. 2024;386:q1645. Published 2024 Jul 23. doi:10.1136/bmj.q1645 Read the full white paper.

Related News